Navigation Links
The Drugs for Neglected Diseases initiative (DNDi) takes the BBVA Foundation Frontiers of Knowledge Award in the Development Cooperation category
Date:2/26/2013

e working on a one-week oral treatment for sleeping sickness which it seems could also be effective against leishmaniasis and Chagas," informs the DNDi director. "If things go well, we may one day have a single drug for these three poverty related conditions at far below the current cost."

DNDi draws its funding in equal measure from public agents – governments and institutions – and the private sector – foundations, NGOs and other organizations. "The situation in Europe is worrying in this respect. That's why we are seeking to diversify, so if a particular government can no longer help, we have other sources on hand to support our activity."

BBVA Foundation Frontiers of Knowledge Awards

The BBVA Foundation primarily engages in the generation and diffusion of scientific knowledge and culture, through ongoing programs in the areas of basic sciences, biomedicine, ecology and conservation biology, social sciences, literary and musical creation, and the visual arts.

Its focus on the core concerns of today's society, like health or the environment, has materialized in major research projects, including those involving the study of cancer. The Foundation's support for research, advanced training and knowledge dissemination is also manifest in a series of award families which not only honor the winners' contributions but also shed a wider light on their fields of work, the values they represent and the combined endeavors of the research and creative communities.

The BBVA Foundation established its Frontiers of Knowledge Awards in 2008 to recognize the authors of outstanding contributions and radical advances in a broad range of scientific and technological areas characteristic of our times. They are in this sense a prize family congruent with the knowledge map and central challenges of the 21st century.

The nominations received from leading universities and research and cu
'/>"/>

SOURCE BBVA Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Biofeedback Headband Lets Pregnant Women Prevent Migraines and TMJ Pain Without Drugs – Holistic Technologies
2. BioInformatics LLC Multi-Sponsor Market Report – In-depth Exploration of the U.S. Market for Biosimilar Drugs
3. Slow-release jelly delivers drugs better
4. Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market is Expected to Reach USD 2.1 Billion Globally in 2018: Transparency Market Research
5. Protein that helps tumor blood vessels mature could make cancer drugs more effective
6. New technology delivers sustained release of drugs for up to 6 months
7. New silk technology preserves heat-sensitive drugs for months without refrigeration
8. Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
9. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
10. Research could lead to new drugs for major diseases
11. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 2008 at 9:00 a.m. Eastern ... ... ALSE ) today reports operational and,financial results for the quarter ended ... http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the progress we ...
... Named Contract Manufacturer of Choice, Based on Its ... Based on its recent,analysis of the pharmaceutical ... BioPharma Solutions (BPS) with the 2008 North,American Frost ... Award at,the 2008 Excellence in Healthcare Innovation Awards ...
... Novavax uses strategies to create vaccines for avian flu ... genetically-engineered virus-like particles (VLPs), ROCKVILLE, Md., ... today that its strategy for treating avian flu,through genetically-engineered ... at Cleveland Clinic 6th Annual Medical Innovation,Summit., Novavax, ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 2Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... soot or black carbon turns out to be ... to carbon dioxide, according to a four-year assessment by an ... soot particles in smoke and smog, contributes about twice as ... 2007 Intergovernmental Panel on Climate Change. "We were surprised at ...
... bacteria and tree, How the protein transport machinery ... Physcomitrella patens is an evolutionary intermediate stage ... have studied how the protein transport system of ... in the chloroplasts of higher plants. They explored ...
... span eight countries from France to Slovenia and harbour an ... found nowhere else. They are widely considered to be ... biodiversity in Europe. But the Alps are not just ... of up to 14 million people and the destination for ...
Cached Biology News:International study: Where there's smoke or smog, there's climate change 2International study: Where there's smoke or smog, there's climate change 3How the protein transport machinery in the chloroplasts of higher plants developed 2How the protein transport machinery in the chloroplasts of higher plants developed 3In search of the big questions: Conserving the European Alps 2In search of the big questions: Conserving the European Alps 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: